BioPharmSignal logoBioPharmSignal

Biotech News

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

Artivion (AORT)ArtivionFDA / regulatory

ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis

Related news

ICCMIceCure Medical2026-09-10 11:58 EST

IceCure Medical Receives Regulatory Approval to Market ProSense® in China

FEMYFEMASYS2026-08-19 13:00 EST

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

VTAKCatheter Precision2026-09-02 20:15 EST

Flyte Secures International Approval to Launch Private Aviation Service Across The Bahamas and Caribbean

SGHTSight Sciences2026-08-04 21:38 EST

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

AORTArtivion2026-07-28 20:10 EST

Artivion to Participate in Upcoming Investor Conferences

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

XAIRBeyond Air2026-08-31 12:00 EST

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

ICCMIceCure Medical2026-08-20 12:10 EST

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

HYPRHyperfine2026-08-20 12:15 EST

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

View all latest news

Artivion

Aortic-Disease Technologies Artivion develops medical devices and implantable tissues for complex aortic and cardiac surgery. Its portfolio is designed around the needs of cardiac and vascular surgeons treating life-threatening aortic disease. Surgical Products The company supplies aortic stent grafts, surgical adhesives, mechanical...

Recent company news

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

AORTArtivion2026-07-28 20:10 EST

Artivion to Participate in Upcoming Investor Conferences

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

AORTArtivion2026-06-29 11:00 EST

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

AORTArtivion2026-06-10 20:10 EST

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Stock data

Close
23.35 USD
Market cap
991.26M USD
Exchange
NYSE
Sector
MedTech
Location
United States